Table 1 Sample demographic and clinical characteristics. The total sample included 465 participants from the National Alzheimer’s Coordinating Uniform Data Set. All participants were diagnosed with normal cognition at the baseline study visit. The final analytic sample included those who remained stable with normal cognition and those who converted to MCI due to AD or AD dementia (n = 56). APOE data were missing for six participants
Variable | Mean (SD) or n (%) | Range |
|---|---|---|
Age at baseline MRI visit | 68.9 (11.8) | 45–100 |
Total length of follow-up (years) | 5.10 (2.14) | 1.45–11.67 |
Total number of follow-up visits | 4.62 (1.91) | 2–10 |
Sex | 146 (31.4%) male | |
Years of education | 15.37 (3.41) | 1–25 |
Ethnicity | 86.9% white, 10.3% AA, 2.8% other | |
APOE ε4 carrier status | 162 (35.3%) carriers | |
Systolic blood pressure | 132 (18.8) | 78–198 |
History of hypertension | 200 (43.0%) | |
History of diabetes | 80 (17.2%) | |
History of hypercholesterolemia | 224 (48.2%) | |
WMH volume at baseline (cm3) | 4.70 (8.71) | 0–61.24 |
Natural log of WMH at baseline | 0.45 (1.52) | − 2.30–4.12 |
Diagnosis at final study visit | ||
Normal cognition | 417 (89.7%) | |
MCI | 22 (4.7%) | |
Dementia | 26 (5.6%) | |
CDR Sum of Boxes at final study visit | 0.55 (1.83) | 0–18 |